EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion

Jin-Ho Choi iD, Sang Nam Lee iD, Jang Hun Heo, Soyoung Park iD, Sei Hyun Park, Yong Taik Lim iD

Advanced Materials · 2026

DOI: 10.1002/adma.74513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Jin-Ho Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Science and Technology, Department of Nano Engineering, School of Chemical Engi…. Hauptthemen laut MEDLINE: Trained Immunity, Spleen, Myelopoiesis, Mycobacterium. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Institute for Basic Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer progression involves systemic immune suppression and tumor recurrence facilitated by increased splenic protumoral myelopoiesis. To address this clinical challenge, we developed an engineered Trojan Mycobacterium as a trained immunity (TI)‐mediated splenic myelopoiesis converter (t‐SMC). This design provides an intravenously injectable anisotropic TI inducer with an aspect ratio of 3.6 for preferential spleen targeting and cellular uptake via a Mycobacterium “peeling‐off and masking‐up” strategy with human serum albumin incorporating an enzyme‑activatable Toll‑like receptor 7/8 agonist that boosts TI activation. t‐SMC induces antitumoral myelopoiesis with metabolic and epigenetic reprogramming in splenic macrophages. This shift toward antitumoral myelopoiesis markedly enriches the tumor microenvironment with inflammatory myeloid effectors in an E.G7‐OVA model, and the adoptive transfer of splenic myeloid cells confirmed the TI‐driven antitumor effect. Furthermore, comparative analysis revealed that the bacterial scaffold (alb‐Mycobac) initiates myeloid reprogramming, but only the integrated TLR7/8 agonist (t‐SMC) crosses the therapeutic threshold for tumor regression. In the MC38 surgical recurrence model, preoperative t‐SMC combined with standard adjuvant αPD‐L1 plus oxaliplatin achieved complete inhibition of recurrence in 50% of treated mice (3 of 6) with 62.5% long‐term survival, establishing TI priming as a translation‐ready preoperative adjuvant that converts immune‐checkpoint non‐responders into responders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trained ImmunitySpleenMyelopoiesisMycobacteriumAnimalsMiceHumansToll-Like Receptor AgonistsCell Line, TumorToll-Like Receptor 7Tumor Microenvironment

Stichwörter der Autor:innen

TLR agonistpreoperative treatmentsplenic myelopoiesistrained immunitytumor recurrence

Substanzen

Toll-Like Receptor AgonistsToll-Like Receptor 7

Autor:innen und Institutionen

  • SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Science and Technology, Department of Nano Engineering, School of Chemical Engineering, and Biomedical Institute For Convergence at SKKU, Sungkyunkwa…

ORCID-Profile: Jin-Ho Choi, Sang Nam Lee, Soyoung Park, Yong Taik Lim

Förderung

  • National Research Foundation of Korea
  • Institute for Basic Science

Zitieren

APA

Choi, J. H., Lee, S. N., Heo, J. H., Park, S., Park, S. H., & Lim, Y. T. (2026). Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion. Advanced Materials. https://doi.org/10.1002/adma.74513

Vancouver

Choi JH, Lee SN, Heo JH, Park S, Park SH, Lim YT. Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion. Advanced Materials. 2026. doi:10.1002/adma.74513

BibTeX
@article{Choi2026,
  author = {Choi, Jin-Ho and Lee, Sang Nam and Heo, Jang Hun and Park, Soyoung and Park, Sei Hyun and Lim, Yong Taik},
  title = {Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion},
  journal = {Advanced Materials},
  year = {2026},
  doi = {10.1002/adma.74513}
}
Kostenlos starten →